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Broadly neutralizing antibodies (bnAbs) against HIV-1 are frequently associated
with the presence of autoreactivity/polyreactivity, a property that can limit their
use as therapeutic agents. The bnAb 4E10, targeting the conserved Membrane
proximal external region (MPER) of HIV-1, displays almost pan-neutralizing
activity across globally circulating HIV-1 strains but exhibits nonspecific off-
target interactions with lipid membranes. The hydrophobic apex of the third
complementarity-determining region of the heavy chain (CDRH3) loop, which is
essential for viral neutralization, critically contributes to this detrimental effect.
Here, we have replaced the aromatic/hydrophobic residues from the apex of
the CDRH3 of 4E10 with a single aromatic molecule through chemical modifica-
tion to generate a variant that preserves the neutralization potency and breadth
of 4E10 but with reduced autoreactivity. Collectively, our study suggests that
the localized accumulation of aromaticity by chemical modification provides a
pathway to ameliorate the adverse effects triggered by the CDRH3 of anti-
HIV-1 MPER bnAbs.
INTRODUCTION
Antibodies, and in particular broadly neutralizing antibodies (bnAbs), have emerged as promising thera-
peutic options against infectious diseases because of their ability to selectively neutralize
target pathogens and to flag them for elimination (Walker and Burton, 2018). Following the advent of single
B cell antibody cloning and high-throughput neutralization assays, the collection of available HIV-bnAbs
has dramatically expanded over the last decade (Klein et al., 2013; Kwong and Mascola, 2012; Sok and Bur-
ton, 2018).
Among the anti-HIV-1 bnAbs isolated so far, those targeting C-terminal residues of the conserved mem-
brane-proximal external region (MPER) of the gp41 subunit consistently display the broadest levels of viral
neutralization (Huang et al., 2012; Krebs et al., 2019; Kunert et al., 2004; Pinto et al., 2019; Stiegler et al.,
2001; Williams et al., 2017; Zhang et al., 2019). That is, Abs targeting this highly conserved HIV-1 Env
sequence block viral infection of a wide range of circulating HIV-1 isolates. These bnAbs, when delivered
passively in animal models, prevent or suppress viral infection (Asokan et al., 2015; Ferrantelli et al., 2003;
Hessell et al., 2010; Huang et al., 2016; Pegu et al., 2014; Stiegler and Katinger, 2003). However, MPER
bnAbs commonly display polyreactivity/autoreactivity, particularly against lipid antigens (Haynes et al.,
2005), a feature that has cautioned against their clinical use in passive therapies (Alving, 2008; Haynes
et al., 2005).
Autoreactivity/polyreactivity of 4E10 has been extensively characterized (Alam et al., 2007; Dennison et al.,
2009; Haynes et al., 2005; Matyas et al., 2009). In fact, the mechanism by which 4E10 binds to theMPER helix
with high affinity requires the insertion of the complementarity-determining region of the heavy chain
(CDRH3) loop into the membrane (Carravilla et al., 2020; Irimia et al., 2016; Rantalainen et al., 2020; Rujas
et al., 2017), explaining the collateral binding to membrane lipids (Haynes et al., 2010). Consistent with thisiScience 24, 102987, September 24, 2021 ª 2021 The Author(s).





Articleobservation, substitutions and deletions of the hydrophobic residues encoded in the key D-gene severely
interfere with binding to native virions and viral neutralization (Alam et al., 2009; Carravilla et al., 2019; Rujas
et al., 2015; Scherer et al., 2010).
Here, we have re-engineered the CDRH3 loop of the human bnAb 4E10 (100WGWL100c) to minimize
off-target interactions with the lipid membrane while preserving its neutralization potency. Specifically,
we have removed the hydrophobic residues at the apex of the CDRH3 and replaced them by a poly-
cyclic aromatic compound (pyrene) previously described to improve antibody binding to native
MPER in HIV-1 virions (Rujas et al., 2020). This trimming-and-grafting strategy concentrated the hydro-
phobicity/aromaticity, otherwise spanned over several residues of the CDRH3, into a single location of
the loop resulting in a re-engineered 4E10 antibody variant with favorable functional properties. In
particular, the resulting 4E10 variant displayed the same neutralization potency and breadth as that
of the wild-type antibody but with notably less autoreactivity against membranes and HEp-2 cells.
Collectively, our data support chemical engineering of CDRH3 hydrophobicity as a strategy to improve
the functional profile of Abs that have evolved to bind epitopes located in the proximity of membrane
interfaces.RESULTS
Removing hydrophobic residues from the tip of the CDRH3 loop decreases 4E10
autoreactivity
Binding of bnAb 4E10 to HIV-1 Env on the virus (Figure 1A) relies on the insertion of the aromatic-rich
CDRH3 apex of sequence – WGWL – into the viral membrane. This interaction has been postulated to sta-
bilize lateral antibody binding to the MPER helical epitope in the environment provided by the membrane
interface (Irimia et al., 2016; Rujas et al., 2017; Scherer et al., 2010). However, the four residues – WGWL –
are not required for specific binding to the MPER epitope in solution because their substitution with the
shorter – SG – sequence yields the antibody variant termed DLoop, which recognizes the epitope-peptide
with comparable affinity and structural interactions to that of the wild-type antibody (Figure 1B) (Rujas et al.,
2015). However, since these hydrophobic residues are required to penetrate the lipid bilayer, the antigen-
binding fragment (Fab) of the DLoop variant lost its ability to interact with membranes made of virus-like
(VL) lipid mixtures emulating the virus envelope (Scherer et al., 2010) (Figure 1C). The inability to interact
with lipids was also demonstrated by the absence of reactivity of DLoop with HEp-2 epithelial cells, which
is a standard method to identify autoantibodies (Dellavance and Andrade, 2019; Haynes et al., 2005) (Fig-
ure 1D). Not surprisingly, the modification introduced in DLoop resulted in the abolition of HIV-1 neutral-
ization activity at concentrations below 200 mg/mL (Figure 1E). Altogether, these data indicate that the
redesign of the hydrophobic apex of the CDRH3 loop is a suitable a strategy to minimize off-target inter-
actions of the antibody 4E10 with lipid membranes, provided that its manipulation does not interfere with






2021.102987Covalent attachment of Fus4 to the trimmed loop restores neutralization breadth and
potency without affecting structural stability
In view of the previous results, we aimed to rescue the biological function of the DLoop variant by
restoring the hydrophobicity of the CDRH3 loop using a single molecule. Since the range of physicochem-
ical properties of natural amino acids is limited, we considered the modification of the antibody with a
chemical compound. To that end, we selected a pyrene-based acetamide compound with four fused aro-
matic rings that we termed Fus4. This is a highly hydrophobic/aromatic molecule that efficiently interacts
with VL membranes (Rujas et al., 2020). Specifically, MD simulations revealed that Fus4 locates within
one leaflet of the bilayer, with its center of mass submerged into the upper sections of the acyl chains, close
to the interface, and with its longitudinal axis almost parallel to the membrane normal (Figure 2A) (Rujas
et al., 2020).
Owing to its large quadrupole moment, Fus4 was predicted to stabilize Fab interaction in the vicinity of
the phosphoglycerol moieties more strongly than the natural Trp residue (containing two fused rings)
(McDonald and Fleming, 2016; Yau et al., 1998). To verify this hypothesis, we modified the CDRH3 apex
with a single Fus4 molecule (Figures 2B and 2D) resulting in the full recovery of the anti-viral potency of
DLoop (Figure 2C). Notably, the presence of a Trp residue at the exact same position as that of Fus4 in
DLoop (H.S100W mutant) did not restore the neutralization activity of the Fab (Figure 2C).2 iScience 24, 102987, September 24, 2021
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Figure 1. Effect of trimming the hydrophobic residues from the CDRH3 loop tip on the functional profile of 4E10
(A) Schematic representation of 4E10 antibody (dark red, heavy chain; orange, light chain) binding to the MPER region (pink) located in the gp41 subunit
(gray) of the HIV-1 Env.
(B) MPER epitope binding by Fabs 4E10 (PDB: 4WY7) and its trimmed version DLoop (PDB: 5CIN) (left and right panels, respectively). Residues from the light
(orange) and heavy (dark red) chain involved in epitope peptide binding with a buried surface area (BSA) > 35 Å are depicted with sticks. The peptide is
shown in magenta. The binding isotherms to the epitope peptide (671NWFDITNWLWYIK683KKK) are also shown. Fitting to a one-site binding model yielded
binding constants (KD-s) of 49 nM and 12 nM for the 4E10 and DLoop Fab, respectively.
(C) Partitioning to VL membranes was measured by a vesicle flotation assay, as schematically described in the left panel. The presence of Fabs in the different
fractions was determined by Western-blot (middle panel). Representative Rhodamine fluorescence emission spectra displayed in the right panel evidenced
the presence of the liposomes in the upper fractions of the 4E10 sample after flotation (pink traces). A similar Rhodamine signal distribution was observed for
all samples measured in this study.
(D) Immunofluorescence staining against HEp-2 epithelial cells. Normalized RFU values are indicated (see Materials and Methods) Scale bars in the
micrographs are 50 mm.
(E) Antiviral activity of Fabs 4E10 (blue) and DLoop (red) against JRCSF (tier 2) and PVO.4 (tier 3) Env-pseudotyped virions (mean valuesGSD for two technical




ArticleNeutralization potency and breadth ofDLoop-Fus4 were further evaluated against a panel of HIV-1 isolates
used previously as an indicator of cross-clade neutralization breadth (Simek et al., 2009) in a standardized
in vitro TZM-bl neutralization assay (Sarzotti-Kelsoe et al., 2014) (Figure 3). The IC50 value and breadth of
DLoop-Fus4 Fab was compared with the unmodified DLoop variant and to the wild-type 4E10 Fab.
DLoop-Fus4 Fab displayed 100% breadth against this panel and neutralized each of the HIV-1 pseudovi-
ruses (PsVs) with the same potency as the parental 4E10 Fab (Figure 3 and Table 1).
X-ray crystallography and thermostability assays ruled out effects on the overall folding of the Fab induced
by the chemical modification with Fus4 (Figures S1 and S2 and Table S1). Thus, together, the functional and
structural data support the idea that synthetic compounds can provide beneficial biological properties
without inducing structural alterations, and hence broaden the antibody engineering toolkit.iScience 24, 102987, September 24, 2021 3
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Figure 2. Fus4 engraftment onto the truncated CDRH3 restores antiviral activity of the Fab DLoop
(A) Depth of insertion and possible orientations adopted in the lipid bilayer by the aromatic compound Fus4. Lipids and Fus4 are depicted with sticks and
spheres, respectively.
(B) Cartoon representation depicting a model of the Fus4 moiety being incorporated in the CDRH3 apex (orange). The epitope peptide is also shown
(magenta).
(C) Cell-entry inhibition assays against JRCSF and PVO.4 PsV (mean valuesGSD for two technical replicates) comparing unmodified DLoop H.S100Cmutant
(green), modified DLoop H.S100C-Fus4 (red), and H.S100W mutant (blue). To facilitate the comparison, IC50 values are indicated.




ArticleFus4 engraftment promotes DLoop binding to the native antigen
To gain further insights into the mechanism by which the neutralization activity of DLoop is recovered
upon covalent addition of Fus4 to the CDRH3 tip, we measured the binding affinity of DLoop-Fus4
Fab to native Env in intact virions using super-resolution stimulated-emission depletion (STED) micro-
scopy (Carravilla et al., 2019). To that purpose, we incubated EGFP.Vpr labeled HIV-1 virions with (i)
the parental 4E10, (ii) the unmodified DLoop Fab or (iii) DLoop-Fus4 Fab, and quantified antibody
signal. Owing to the linear nature of the STED phenomenon, the number of photons recorded by
the detector is directly proportional to the number of bound Fabs (Figure 4A), which permits the esti-
mation of the antibody binding affinity. Consistent with the neutralization data (Figures 1E and 3),
almost no binding to native Env was observed when employing DLoop Fab. In contrast, the chemically
modified DLoop-Fus4 antibody showed a binding profile remarkably similar to the parental 4E10 Fab
(Figure 4A).
These observations were confirmed using blue native polyacrylamide gel electrophoresis (BN-PAGE)
gel mobility shift assays (Leaman and Zwick, 2013) to measure binding to virion-associated Env trimers
(Figure 4B). As expected, the observed increase in neutralization with DLoop-Fus4 Fab matched with
increased binding to virion-associated Env trimers, as there is a similar upward gel mobility shift of
the Env spike band upon incubation of virions with DLoop-Fus4 and parental 4E10 Fab. The inability
of DLoop to neutralize the virus is related to a meager capacity of this variant to bind to the Env
trimer, as seen by the negligible shifts in the BN-PAGE bands (Figure 4B). Overall, these data confirm4 iScience 24, 102987, September 24, 2021
Figure 3. Modified DLoop-Fus4 displays similar potency and breadth to that of parental 4E10
Representative neutralization titration curves of DLoop-Fus4 (solid red triangles, lines), parental 4E10 (solid blue circles, lines), and DLoop (empty red
squares, dashed lines) against a panel of eight HIV-1 isolates previously described as an indicator of cross-clade neutralization breadth (Simek et al., 2009)




Articlethat Fus4 replaces the biological function of the hydrophobic residues at the CDRH3 apex of 4E10
and allows binding to native MPER helices, which results in a stable Fab-Env complex and virus
neutralization.
Trimming-grafting the CDRH3 loop apex ameliorates the autoreactivity profile of 4E10
Next, we tested the autoreactivity profile of DLoop-Fus4 Fab by measuring binding to HEp-2 epithelial
cells (Figures 5A and 5B). Notably, cells treated with the modified DLoop-Fus4 Fab showed remarkably
low fluorescence intensity levels, resembling the autoreactivity profile of the unmodified DLoop variant
(Figure 1D). To confirm that concentrating interfacial hydrophobicity at a single position does not trans-
late into enhanced autoreactivity, we replaced W100b of parental 4E10 Fab with Fus4, also by chemical
modification, to generate the – W-G-Fus4-L – tip. Consistent with the results obtained for DLoop, the
presence of Fus4 did not significantly increase the interaction of modified 4E10 with HEp-2 cells with
respect to the unmodified antibody. A similar binding profile was obtained for both Fab 4E10 and
Fab 4E10-Fus4, in spite of the latter having two additional hydrophobic/aromatic fused rings at
the CDRH3 (Figures 5A, 5B and 1D). However, when the interfacial hydrophobicity was distributed
through the CDRH3 instead of being concentrated at the H.W100b position, the resulting Fab (4E10-
3W) displayed a stronger staining of HEp-2 cells than that observed by the 4E10 Fab, indicating a
greater autoreactivity (Figures 5A, 5B and 1D). In this case, the two additional fused rings correspondediScience 24, 102987, September 24, 2021 5
Table 1. Fus4 conjugation-induced DLoop neutralization rescue measured against a variety of HIV isolates
IC50 (mg/ml)
Virus Clade Tier 4E10 Dloop Dloop-Fus4
94UG103 A 2 1.6 >50 2.5
92BR020 B 2 1.8 >50 2.0
ADA.CM B 2 2.7 >50 2.6
IAVI C22 C 2 1.5 >50 1.9
92TH021 AE 2 0.18 >50 0.28
BG505 A 2 0.72 >50 0.46
92RW020 A 2 1.0 >50 0.53




Articleto an additional Trp residue at the tip of the CDRH3 loop at the position of the hydrophobic residue
Leu (– W-G-W-W – tip).
Notably, this set of CDRH3 mutants further confirmed the apparent lack of correlation between autoreac-
tivity and antibody antiviral (neutralization) activity (Figure 5B). On the one hand, 4E10-Fus4 displayed a
30-fold increase in neutralization potency in comparison to the parental 4E10 without a significant increment
on its autoreactivity levels. On the other hand, the potency of the 4E10-3W Fab did not appreciably improve,
whereas its autoreactivity levels significantly increased. Thermostability assays demonstrated that themodi-
fication of the sequence of the CDRH3 loop did not alter the melting and aggregation temperature of the
Fabs, discarding that defects in stability could influence their autoreactivity profile (Figure S2).
The results of Fab binding to VLmembranes were also consistent with the above observations (Figure 5C).
Following the same trend observed for DLoop, the modified DLoop-Fus4 Fab did not associate sponta-
neously with vesicles made of the VL mixture. Similarly, modification of the parental antibody with Fus4
did not change its membrane partitioning behavior compared to that of the parental 4E10 Fab. In
both cases, the ability to interact with lipid membranes was dependent on the presence of the anionic
phospholipid phosphatidylserine (Figure 5C). In contrast, the 4E10 3W Fab bound to VL membranes
also in the absence of PS, highlighting the influence of the hydrophobic component of this Fab in driving
membrane binding, and consequently in its autoreactive profile. Overall, the data gathered in this section
suggest that strategies to narrow the hydrophobic distribution within the CDRH3 loop could be em-
ployed to improve the properties of antibodies directed against membrane embedded epitopes
(Figure 6).DISCUSSION
Antibody polyreactivity generally correlates with poor in vivo half-life of antibodies (Rudicell et al., 2014;
Sievers et al., 2015), requiring their modification by protein engineering to improve their biophysical prop-
erties and pharmacokinetic profiles. However, the optimization of sequences aiming to reduce polyreac-
tivity may as well abolish biological activity. Several HIV antibodies targeting the MPER helix of Env harbor
a hydrophobic patch of residues at the apex of their CDRH3 loop, which must interact with the viral mem-
brane in order to reach the MPER moiety. Those hydrophobic residues, that are critical for the neutralizing
activity of the antibody, also contribute to their unspecific binding to membranes.
In this study, we focused on the HIV-1 antibody 4E10, an anti-MPER antibody that shows some degree of
polyreactivity. We aimed at developing a strategy to minimize its polyreactivity, while preserving antibody
potency and breadth. We used site-selective chemical modification to concentrate in a single compound
(Fus4) the functional equivalent of the hydrophobicity/aromaticity of the four residues at the apex of the
CDRH3 – WGWL – of 4E10. This strategy yielded a 4E10 variant with an optimized balance of hydrophobic-
ity in the CDRH3 that evaded unspecific lipid binding while facilitating its functional insertion into the viral
membrane. This result agrees with previous studies in which it was postulated that the formation of an
induced lipid binding site upon epitope binding accounted for the low polyreactivity of a MPER antibody
(Krebs et al., 2019; Zhang et al., 2019). In the following, we discuss possible mechanisms to explain the
outcome of this approach.6 iScience 24, 102987, September 24, 2021
A B
Figure 4. Fus4 conjugation results in efficient binding to native HIV-1 Env
(A) Top: Schematic representation of the correlation between fluorescence intensity signal (pink-antihuman- STAR RED) and number of Fabs bound to
JRCSF-pseudotyped virions (green- Vpr.EGFP) measured by STED microscopy. Representative micrographs with no (top), low (middle) or high number
(bottom) of bound antibodies are shown. Right panel: Representative micrographs and quantification of the fluorescence intensity of the bound Fab signal in
individual virions from two independent experiments. Virions incubated only with the antihuman STAR RED secondary antibody were added as a negative
control. Lines represents the mean value and whiskers the 5th and 95th percentiles. Scale bars in the micrographs are 100 nm.
(B) Binding comparison of Fabs 4E10, DLoop and DLoop-Fus4 to native Env trimers on HIV-1 virions. Formation of Env-Fab complexes were resolved by




ArticleInsertion of the apex of the 4E10 CDRH3 loop into the viral membrane depends on favorable nonpolar in-
teractions with the water:lipid interface (DGnp) but also on the bilayer effects (DGbilayer) that usually oppose
such insertion. These effects comprise the changes in conformation and reduced mobility of the inserted
peptide chain, and the deformation energy of the lipid bilayer (White andWimley, 1999) (Figure 6). It should
be noted that the latter will be of special relevance during insertion of the apex of the loop due to (i) the
high degree of flexibility observed in solution for this element in the apo form of the antibody (Rujas et al.,
2015) and (ii) the fact that a portion of the non-H-bonded antibody chain must penetrate the membrane
interface (White and Wimley, 1999). In the specific case of 4E10, the negative bilayer effect could be
partially overcome by the Trp residues at the apex, since their side chains favorably partition into the inter-
facial region of lipid bilayers (Wimley andWhite, 1996; Yau et al., 1998) presumably due to their quadrupole
moment and planarity (Yau et al., 1998). In this context, we hypothesized that Fus4 concentrates and inten-
sifies those favorable molecular properties in a single moiety and at a single position, thus favoring pene-
tration of the antibody loop in the membrane. In addition, we believe that the bilayer effect would be less
intense when employing a CDRH3 loop of reduced size, like in DLoop, reducing the entropy loss upon
insertion. Hence, these factors could explain the recovery of the biological function after chemical modi-
fication of this antibody variant.
Notably, recovery of the biological function of 4E10 took place without a significant development of off-
target interactions with bare membranes or with HEp-2 cells. As indicated previously, building favorable
interactions between Trp residues and the lipid bilayer interface is expected to contribute favorably to
the insertion of the parental 4E10 CDRH3. However, distributing aromaticity along the CDRH3 loop across
multiple Trp residues also enlarges the hydrophobic surface of the antibody exposed to the solventiScience 24, 102987, September 24, 2021 7
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Figure 5. Fus4 engraftment onto DLoop’s CDRH3 does not rescue autoreactivity
(A) Immunofluorescence staining against HEp-2 epithelial cells. Normalized RFU values are indicated. Scale bars in the
micrographs are 50 mm.
(B) Quantitative comparison of HEp-2 cells staining and neutralization potency (IC50 neutralization values against JRCSF-
pseudotyped virions). Mean G SD values obtained from three independent experiments are plotted.
(C) Spontaneous water-membrane partitioning measured in vesicle flotation assays. VL composition is compared with VL




Article(accessible surface area [ASA] values in Figure 6). We speculate that increasing the surface of this patch
beyond a certain level results in the promotion of nonspecific interactions with the membrane, whereas
the reduction of the hydrophobic surface accessible to the solvent as shown for DLoop-Fus4 is expected
to mitigate off-target non-polar interactions of the CDRH3 loop (Figure 6). Thus, aromaticity accretion at
a single position of the loop appears to ensure stable Fab association with Env on virions.
Anti-MPER antibodies are important HIV therapeutic candidates due to their extraordinary breadth. How-
ever, their clinical use might be limited by their potency (Manrique et al., 2007; Mendoza et al., 2018).
Consistent with the importance of antibody potency and breadth, the recent clinical trials HVTN8 iScience 24, 102987, September 24, 2021
Figure 6. Model for Fus4 effects on CDRH3 function
A silhouette model of the CDRH3 apex of antibodies DLoop, DLoop-Fus4, 4E10 and 4E10 3W was employed to illustrate
the composition of each loop. The propensity of interacting with lipid membranes was represented as two opposing
forces, a favorable energy driven by nonpolar interactions (DGnp, green arrow), and an unfavorable energy caused by the
bilayer effect (DGbil, red line). The accessible surface area (ASA) of the exposed residues was calculated using the
PDBePISA server (Krissinel and Henrick, 2007). The calculations were carried out with PDB: 5CIN (for DLoop, chain H), and
4XBG (for 4E10, chain A). Models of DLoop-Fus4 and 4E10 3W were generated from 5CIN and 4XBG, respectively and
ASA calculated accordingly in the PDBePISA server. The autoreactivity outcome of the two strategies, i.e. the use of




Article704/HPTN 085 with the bnAb VRC01 established an IC80 threshold of 1 mg/mL to achieve in vivo protection
against an HIV strain (Corey et al., 2021). Hence, the near pan-neutralization breadth of MPER antibodies
warrants engineering efforts to improve their potency. In this regard, we have previously shown that site-
selective chemical modification of the anti-MPER bnAb 10E8 with aromatic residues dramatically increased
its capacity to block viral infection (Rujas et al., 2020). Similarly, here we showed that aromatic grafting in the
parental 4E10 resulted in 30-fold improvement of the neutralization potency of this antibody. However, it
should be noted that Fus4 could induce anti-drug antibodies in vivo, decreasing its effectiveness and hence
the potential impact of Fus4 on antibody immunogenicity needs to be studied. In addition, the need of a
conjugation step increases production complexity likely affecting the yield of the final product. These are
important aspects that should be considered if this approach were to be followed in developing a clinical
product, over more conventional methods previously employed (Kwon et al., 2016).
Finally, several antibodies with a more favorable biological profile than 4E10 have been described,
lowering the interest of this antibody as a clinical candidate. However, some of those share the same germ-
line V/D-region genes of 4E10 (Krebs et al., 2019; Zhang et al., 2019). Remarkably, these Abs engage MPER
following a common molecular mechanism of recognition, yet they present diverse polyreactivity profiles
and some possess shorter CDRH3s. Hence, it will be interesting to explore the potency-enhancement ca-
pacity of Fus4 conjugation to bnAbs of the 4E10 class like PGZL1 that has a shorter CDRH3 and reduced
polyreactivity compared with 4E10 (Krebs et al., 2019; Zhang et al., 2019), or with other antibodies that
target membrane proximal epitopes, to explore if this approach can be applied to more clinically relevant




ArticleOverall, our study suggests that the CDRH3 of 4E10 might act as a Velcro-like tightening system to form a
stable Env-complex incompatible with fusion progression and puts forward the possibility that chemical
engineering of CDRH3 hydrophobicity could be used as a general strategy to improve recognition of epi-
topes proximal to the membrane. In addition, these data provide an alternative strategy to increase hydro-
phobicity without generating unspecific lipid interactions by concentrating interfacial hydrophobicity at a
single position.
Limitations of the study
In this study, a single HIV antibody, i.e., 4E10, has been selected to validate the use of aromatic grafting as a
method to preserve/improve binding to membrane embedded epitopes without generating off-target ef-
fects. However, we acknowledge that the clinical use of 4E10 is limited due to the emergence of more
potent antibodies, and that applying this strategy to a larger set of antibodies will be needed to determine
the applicability of this method.
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KEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Donkey anti-Human IgG Abberior STAR RED Abberior CTRED-1054; RRID:AB_2877172
Goat anti-Human IgG (Fab specific) Sigma I5260; RRID:AB_260206
Rabbit anti-human IgG-HRP Santa Cruz Biotechnology sc-2769; RRID:AB_656966
Mouse anti-goat IgG-HRP Santa Cruz Biotechnology sc-2354; RRID:AB_628490
Bacterial and Virus Strains
E. coli T7Shuffle New England Biolabs C3026J
E. Coli DH5a competent cell Invitrogen 18265017
Chemicals, Peptides, and Recombinant Proteins
2-Iodo-N-(pyren-1-yl) acetamide (Fus4) Life Technologies P29
gp41 MPER peptide ProteoGenix N/A
1-palmitoyl-2-oleoylphosphatidylcholine (POPC) Avanti Polar Lipids 42773
1-palmitoyl-2-oleoylphosphatidylethanolamine (POPE) Avanti Polar Lipids 01991
1-palmitoyl-2-oleoylphosphatidylserine (POPS) Avanti Polar Lipids 840034C
N-palmitoylsphingomyelin (SM) Avanti Polar Lipids 85615
Cholesterol (Chol) Avanti Polar Lipids C8667
DNase I PanReac AppliChem A3778,0010
EDTA-free protease inhibitor mixture Roche 11873580001
MEM Non-essential Amino Acid Solution Thermo Scientific 11140050
Sodium Pyrubate Thermo Scientific 11360070
Opti-MEM I Reduced-Serum Medium Thermo Scientific 11058021
KOD-Plus mutagenesis kit Toyobo SMK-101
Bright-Glo luciferase reagent Promega E2610
PEI, MW 25 kDa Polysciences 23966-1
DMEM Growth Medium Life Technologies 10313-039
Fetal Bovine Serum Life Technologies 10437-028
NuPAGE 3-8% Tris-acetate Gels Life Technologies EA03755BOX
Tris-glycine Native Sample Buffer Life Technologies LC2673
Coomassie Brilliant Blue G250 Sigma 27815
n-Dodecyl-beta-Maltoside (DDM) Pierce 89903




Trifluoroacetic acid Thermo scientific 28904
Water, Optima LC/MS grade Fischer chemical W6-1
Acetonitrile, Optima LC/MS grade Fischer chemical A955-212
Protein Calibration Standard 1 mixture Bruker Daltonics 206355
Poly-L-lysine solution Sigma-Aldrich P8920
Bovine Serum Albumin (fatty acid free) Sigma-Aldrich A7030
PBS1x without calcium and magnesium Thermo Fisher Cat#12037539
PenStrep Gibco Cat#15140-122
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Critical Commercial Assays
Kallestad HEp-2 Kits BioRad 30471
Deposited Data
4E10-Fus4 Protein Data Bank 7EKB
Dloop-Fus4 Protein Data Bank 7EKK
Experimental Models: Cell Lines
Human: HEK293T Cells ATCC CRL-3216
Human: TZM-bl Cells NIH AIDS Reagent Program 8129
Recombinant DNA
pCOLADuet-1 expression plasmid Sigma-Aldrich 71406
4E10 Fab pCOLADuet-1 wild-type and mutants This paper N/A
pWXLP-GFP Patricia Villacé, CSIC N/A
pCMV8.91 Patricia Villacé, CSIC N/A
PVO, clone 4 (SVPB11) Expression plasmid NIH AIDS Reagent Program 11022
JRCSF Expression plasmid Jamie Scott, SFU N/A
pSG3DEnv NIH AIDS Reagent Program 11051
ADA.CM Expression plasmid Leaman and Zwick, 2013 N/A
92RW020.5 Expression plasmid NIH AIDS Reagent Program 3097
94UG103 Expression plasmid D. Burton, Scripps (Simek et al., 2009) N/A
92BR020 Expression plasmid NIH AIDS Reagent Program 1780
92TH021 Expression plasmid D. Burton, Scripps (Simek et al., 2009) N/A
IAVI C22 Expression plasmid D. Burton, Scripps (Simek et al., 2009) N/A
BG505 Expression plasmid NIH AIDS Reagent Program 11518
P16055 Expression plasmid NIH AIDS Reagent Program N/A
pEGFP.Vpr NIH AIDS Reagent Program 11386
Software and Algorithms
GraphPad Prism 8 GraphPad N/A
Autoflex III Bruker Daltonics N/A
Autoflex III Bruker Daltonics N/A
Pymol Molecular Graphics System Schrödinger N/A
Imspector software Abberior Instruments N/A
STED analysis program Galiani et al., 2016 https://doi.org/10.5281/zenodo.1465920.
OriginPro 2019b (9.6.5.169) OriginLab Corporation N/A
biorender biorender.com https://biorender.com/
Microcal Origin 7.0 OriginLab N/A
UNit analysis software Unchained Labs N/A
Coot Emsley et al., 2010 N/A
PDBePISA Krissinel and Henrick, 2007 N/A
UCSF Chimera Pettersen et al., 2004 N/A
Other
ZipTip C4 micro-columns Millipore ZTC04S096
Ground Steel massive 384 MALDI target plate Bruker Daltonics 8074115
Nickel-nitrilotriacetic acid (Ni-NTA) affinity column GE-Healthcare 10431065
MonoS ion exchange chromatography (IEC) column GE-Healthcare 17516801
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Further information and requests for resources and reagents should be directed to and will be fulfilled by
the lead contact, Jose Luis Nieva (joseluis.nieva@ehu.es).
Materials availability
All unique/stable reagents generated in this study are available from the Lead Contact with a completed
Materials Transfer Agreement
Data and code availability
The authors declare that all relevant data are available within the article and its Supplemental information
files or from the corresponding author upon reasonable request. The crystal structures of 4E10-Fus4 and
Dloop-Fus4 (Table S1) are available from the Protein Data Bank under accession codes 7EKB and 7EKK,
respectively. This study did not generate new code.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Escherichia coli T7-shuffle strain was grown in Luria Broth medium following the specifications of the
supplier.
HEK293T and TZM-bl cells were cultured in DMEM (Dulbecco’s Modified Eagle Medium), supplemented
with 1 mM sodium pyruvate, 1 mMMEMNon-Essential Amino Acids Solution and 10% FBS, in a humidified
incubator at +37C, supplied with 5%CO2. For cell seeding, cells were washed with phosphate buffer saline
(PBS) and then detached with trypsin/EDTA solution (Thermofisher).
METHOD DETAILS
Production and site-selective chemical modification of Fabs
Antibody Fab sequences were cloned in the plasmid pColaDuet and expressed in Escherichia coli
T7-shuffle strain. Recombinant expression was induced at 18C overnight with 0.4 mM isopropyl-D-thioga-
lactopyranoside when the culture reached an optical density of 0.8. Cells were harvested and centrifuged at
8,000 3 g, after which they were resuspended in a buffer containing 50 mM HEPES (pH 7.5), 500 mM NaCl,
35 mM imidazole, DNase (Sigma-Aldrich, St. Louis, MO) and an EDTA-free protease inhibitor mixture
(Roche, Madrid, Spain). Cell lysis was performed using an Avestin Emulsiflex C5 homogenizer. Cell debris
was removed by centrifugation, and the supernatant loaded onto a nickel-nitrilotriacetic acid (Ni-NTA) af-
finity column (GE Healthcare). Elution was performed with 500 mM imidazole, and the fractions
containing the His-tagged proteins were pooled, concentrated and dialyzed against 50 mM sodium phos-
phate (pH 8.0), 300 mM NaCl, 1 mM DTT, and 0.3 mM EDTA in the presence of purified protease Tobacco
etch virus (Kawai et al., 2011). Fabs were separated from the cleaved peptides containing the His6x tag by an
additional step in a Ni-nitrilotriacetic column. The flow-through fraction containing the antibody was dia-
lyzed overnight at 4C against sodium acetate (pH 5.6) supplemented with 10% glycerol and subsequently
loaded onto aMonoS ion-exchange chromatography (IEC) column (GE Healthcare). Elution was carried out
with a gradient of potassium chloride and the fractions containing the purified Fab concentrated and dia-
lyzed against a buffer containing 10 mM sodium phosphate (pH 7.5), 150 mM NaCl, and 10% glycerol.
Site-selective chemical conjugation was carried out as previously described (Rujas et al., 2020). In brief, a
cysteine-substituted Fab derivative was first generated by site-directed mutagenesis using the KOD-Plus
mutagenesis kit (Toyobo, Osaka, Japan). Mutation H.S100C and W100bC was generated in the case of
DLoop-Fus4 and 4E10-Fus4, respectively. Next, the mutated Fabs were conjugated to the sulfhydryl-
specific iodoacetamide derivative of the compound Fus4 upon incubation of the Fabs at 37C overnight
with a 103 excess of the compound. Conjugation was monitored by matrix-assisted laser desorption/
ionization (MALDI) mass spectrometry.
Isothermal titration calorimetry (ITC)
ITC experiments were performed with a VP-ITC microcalorimeter (MicroCal, Northampton, MA) at
20C. Fabs of 4E10 or DLoop each at 3 mM previously dialyzed against PBS buffer (10 mM sodium phos-




Articleresuspended in the same buffer. Peptide dilution heat was subtracted for data analysis. The binding iso-
therms were fitted to a one-site binding model using the program ORIGIN 7.0 (MicroCal, Northampton,
MA). The fitting procedure yielded the stoichiometry (n) and the binding constant (KD) of the binding
reaction.
Thermostability assay
The melting temperature (Tm) and aggregation temperature (Tagg) of the different Fabs was determined
using a UNit system (Unchained Labs). Samples were prepared at 1 mg/mL in 10 mM sodium phosphate
(pH 7.5), 150 mM NaCl, and 10% (v/v) glycerol and subjected to a thermal ramp from 25 to 95C with
1C increments. Tm values were calculated from the barycentric mean fluorescence. On the other hand,
Tagg values were determined as the temperature at which 50% increase in the static light scattering at a
266 nm wavelength relative to baseline was observed. The average and the standard error of two measure-
ments were calculated using the UNit analysis software.
Mass spectrometry analysis
Prior to the measurement, conjugated antibodies were desalted using ZipTip C4 micro columns (Milli-
pore) (2 mL sample) with 0.5mL SA buffer (sinapinic acid, 10 mg/mL in [70:30] Acetonitrile:Trifluoroacetic
acid 0.1%), and spotted onto a Ground Steel massive 384 target plate (Bruker Daltonics). Mass determina-
tion was performed bymatrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) analysis in an
Autoflex III (Bruker Daltonics). Mass calibration was performed externally with a Protein Calibration Stan-
dard 1 (Bruker Daltonics) mixture in the same mass range as the samples. Data acquisition, peak peaking
and subsequent spectra analysis were performed using flexAnalysis 3.0 software (Bruker Daltonics).
Polyreactivity assays
HIV-1 negative human epithelial HEp-2 (Kallestad ANA/HEp-2) were incubated with 25 mL from a Fab stock
solution diluted to 50 mg/mL. Anti-Human IgG (Fab specific)FITC antibody produced in goat was used as
the secondary antibody. Images were acquired on a Leica TCS SP5II microscope (Leica Microsystems
GmbH, Wetzlar, Germany). Cells were imaged through a 363 water-immersion objective (NA = 1.2) and
1024 3 1024 pixel images were acquired at 200 Hz per scanning line. Images obtained under the same
gain/detector conditions were subsequently analyzed using the FIJI distribution of ImageJ (Schindelin
et al., 2012) as follows: First, pixel intensities within several background regions were measured to estimate
the average value of the background; next, taken such value as threshold, the average value of the pixel
intensities above that threshold was measured for each sample, and verified that corresponded to areas
covered by cells; intensity values were finally referred to a 0–100% scale, were 0% and 100% relative light
unit values correspond respectively to those of the negative and positive ANA controls provided by the
manufacturer.
Direct interaction with membranes was evaluated in vesicle flotation experiments as previously described
(Rujas et al., 2018). In brief, large unilamellar vesicles were prepared at a concentration of 1.5 mM lipid of
the VL mixture DOPC:DOPE:DOPS:SM:Chol (14:16:7:17:46) (Scherer et al., 2010). 100 mL of a sample con-
taining 0.5 mol % Rho-PE-labeled VL vesicles was adjusted to a sucrose concentration of 1.4 M in a final
volume of 300 mL, and subsequently overlaid with 400 mL- and 300 mL-layers of 0.8 M and 0.5 M sucrose,
respectively. The gradient was centrifuged at 436,000 3 g for 3 h at 4C in a TLA 120.2 rotor (Beckman
Coulter). After centrifugation, four 250 mL-fractions were collected. The presence of Fabs in the different
fractions and in the original sample (input) was revealed by Western Blot analysis after Tris-Tricine SDS-
PAGE separation. The presence of liposomes in the different fractions was determined after measuring
the fluorescence emission of the Rho-PE probe (Thermo Fisher Scientific, Waltham, Massachusetts, USA)
Crystallization, data collection and processing, and structure refinement
The 4E10-Fus4:peptide complex at 3 mg mL1 in PBS buffer supplemented with 10% glycerol was crystal-
lized in a solution composed of 200 mM ammonium sulfate, 100 mM sodium acetate (pH 4.6) and 12% PEG
4,000 by themethod of sitting-drop. Similarly, theDLoop-Fus4:peptide complex at 3mgmL1 in PBS buffer
supplemented with 10% glycerol was crystallized in a solution composed of 200 mM ammonium sulfate and
PEG 4,000, also using the method of sitting-drop. Suitable crystals of 4E10-Fus4 or DLoop-Fus4 in complex
with epitope peptide were harvested, briefly incubated in mother liquor supplemented with 20–30% (v:v)




Articlecrystals were collected in beamline XALOC at the ALBA synchrotron (Cerdanyola del Valles, Spain) under
cryogenic conditions (100 K). Diffraction images were processed with the program MOSFLM and merged
and scaled with the program SCALA (Evans, 2006) of the CCP4 suite (Winn et al., 2011). The structure of the
complex of epitope peptide with 4E10-Fus4 and DLoop-Fus4 were determined by the molecular replace-
ment method using the coordinates of unmodified 4E10 (PDB entry code 4WY7) (Apellaniz et al., 2015) and
the coordinates of DLoop (5CIN) (Rujas et al., 2015), respectively, with the program PHASER (McCoy et al.,
2007). The models were refined with the programs REFMAC5 (Murshudov et al., 1997) and refinedmanually
with COOT (Emsley et al., 2010). Validation was carried out with PROCHECK (Laskowski et al., 1993). Other
structure calculations were carried out with CHIMERA (Pettersen et al., 2004). Data collection and structure
refinement statistics are given in Table S1.
Virus production and neutralization assays
Antibody potency was evaluated in pseudovirus (PsV)-based cell-entry assays (Louder et al., 2005). HIV-1
PsVs were produced by transfection of human kidney HEK293T cells with the full-length Env clone JRCSF
(kindly provided by Jamie K. Scott and Naveed Gulzar, Simon Fraser University, BC, Canada) and the PVO.4
molecular clone (obtained from the AIDS Research and Reference Reagent Program (ARRRP)). Cells were
co-transfected with vectors pWXLP-GFP and pCMV8.91, encoding a green fluorescent protein and an Env-
deficient HIV-1 genome, respectively (provided by Patricia Villace, CSIC, Madrid, Spain). After 24 h, theme-
dium was replaced with Optimem-Glutamax II (Invitrogen Ltd, Paisley, UK) without serum. Two days after
transfection, the PsV particles were harvested, passed through 0.45 mmpore sterile filters (MillexHV,Milli-
pore NV, Brussels, Belgium) and finally concentrated by ultracentrifugation in a sucrose gradient. HIV entry
was determined using CD4+CXCR4+CCR5+ TZM-bl target cells (ARRRP, contributed by J. Kappes). To that
end, HIV PsVs were first diluted to 10–20% tissue culture infectious doses in DMEM supplemented with
inactive serum, and added to the modified and WT Fabs. Infection levels after 72 hours were inferred
from the number of GFP-positive cells as determined by flow cytometry using a BD FACSCalibur Flow
Cytometer (Becton Dickinson Immunocytometry Systems, Mountain View, CA).
The ability of Fab to inhibit infection by a diversity of HIV isolates was tested using a previously described
neutralization assay and panel of PsVs (Rujas et al., 2018). Briefly, HIV-1 PsVs, were produced by co-trans-
fection of Env-complementation plasmid and the HIV-1 backbone plasmid pSG3DEnv in HEK293T cells.
Fabs, diluted in cell culture media starting at 50 mg/mL and proceeding in a 5-fold dilution series, were
added to PsVs and incubated for 1h at 37C. Fab/virion mixtures were then added to TZM-bl target cells
and further incubated for 72 h at 37C. Cells were lysed and luciferase intensity was read using Bright-
Glo luciferase reagent (Promega) and a Synergy H1 plate reader (BioTek).
Binding to native Env by super-resolution fluorescence STED microscopy of single virions
Concentrated JRCSF pseudotyped virus particles containing Vpr.EGFP were adhered to poly-L-lysine
(Sigma) coated glass coverslips for 15 min. Then, coverslips were blocked using 2% fatty acid free
bovine serum albumin (Sigma)/PBS for 15 min. Fabs (25 ng/mL) were incubated for 1 h in blocking buffer
at a 25 ng/mL concentration and revealed upon incubation with anti-human Abberior STAR RED (Abberior
GmbH) conjugated Ab. The sample was washed and mounted in PBS, followed by STED imaging. All steps
were carried out at RT.
Imaging was performed on a STED microscope based on a modified Abberior Instrument RESOLFT
QUAD-P super-resolution microscope (Abberior Instruments GmbH). The sample was excited and the
emission collected using a 1003/1.40 NA UPlanSApo oil immersion objective (Olympus Industrial, South-
end-on-Sea, UK). The fluorescence signal was descanned, passed through an adjustable pinhole (Thorlabs
Limited, Ely, UK) and detected by single photon counting avalanche photo diodes (SPCM-AQRH-13, Exce-
litas Technologies) with appropriate fluorescence filters (AHF Analysentechnik). All acquisition operations
were controlled by Imspector software (Abberior Instruments). Resolution was typically around 40 nm.
Emitted photons were recorded line by line in STED microscopy mode, and Vpr.eGFP was next imaged
in confocal mode to determine the location of HIV-1 virions.
Image analysis was performed using Python scripting language and custom written functions (Carravilla
et al., 2019; Galiani et al., 2016). Individual virions were identified from the Vpr.eGFP channel using an
intensity maximum finding algorithm on a Gaussian smoothed image (s = 2.0). A circular region (diameter,




Articlequantified at said region and compared to a random region within 90-pixels constrained not to present
Vpr.EGFP signal. To permit comparison between independent experiments, the STAR RED emission signal
was normalized to that of the median intensity value of the 4E10 sample.Blue native (BN)-PAGE Western Blot
BN-PAGE gel mobility shift assays were performed using virions produced by transfection of the
infectious molecular clone plasmid pLAI displaying the Env variant ADA.CM (Leaman and Zwick, 2013).
Virions and a dilution series of Fab were incubated at RT for 30 min. The virion/Ab mixture was solubilized
in 1% n-Dodecyl b-D-maltoside (DDM; Sigma) for 20 min on ice, and then run on a 3–8% gradient Tris-
Acetate NuPAGE gel (ThermoFisher) in Tris-Glycine Native Sample Buffer (ThermoFisher), supplemented
with 0.25% Coomassie G-250. Gels were run for 3 h at 150 V in Tris-Glycine Native Running Buffer
(ThermoFisher) + 0.002% Coomassie G-250. Proteins were transferred onto PDVF membrane and Western
blotted using a cocktail of primary antibodies to gp120 (F105, 2G12 and HGN194, 2 mg/mL each) and
gp41 (10E8, 2F5, and 7B2, 1 mg/mL each) followed by a goat anti-human-Fcg-HRP secondary antibody
(Jackson). The blot was developed using ECL Plus Substrate (Pierce) and a ChemiDoc XRS + Imaging Sys-
tem (Bio-Rad).18 iScience 24, 102987, September 24, 2021
